NCT01174693 (MAESTRO) is a Phase 4 clinical trial of Triflusal in Cerebral Infarction, sponsored by Gangnam Severance Hospital.

Who is sponsoring NCT01174693?

NCT01174693 is sponsored by Gangnam Severance Hospital.

What drugs are being tested in NCT01174693?

Interventions in NCT01174693: Triflusal, Clopidogrel.

What condition does NCT01174693 study?

NCT01174693 studies Cerebral Infarction.

Is NCT01174693 still recruiting?

NCT01174693 is currently completed. Last updated 16 March 2015.

Last reviewed 2015-03-16 · How we verify

NCT01174693: MAESTRO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Triflusal and Clopidogrel Effect in Secondary Prevention of Stroke Based on the Cytochrome P450 2C19 Genotyping

Completed Phase 4 Last updated 16 March 2015

What this trial tests

Phase 4 trial testing Triflusal in Cerebral Infarction in 795 participants. Completed in 1 March 2015.

Timeline

1 March 2010

Primary endpoint
1 December 2014

1 March 2015

Quick facts

Lead sponsor	Gangnam Severance Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	795
Start date	1 March 2010
Primary completion	1 December 2014
Estimated completion	1 March 2015
Sites	18 locations across South Korea

Drugs / interventions tested

Triflusal (TRIFLUSAL) — full drug profile →
Clopidogrel (clopidogrel) — full drug profile →

Conditions studied

Cerebral Infarction — all drugs for Cerebral Infarction →

Sponsor

Gangnam Severance Hospital

Who can join

20 and older, any sex, with Cerebral Infarction. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Time to first recurrent stroke
Time frame: 2.8 to 4 years
The study will finish at least 2 years after the recruit of 1080th patients. Until the finish, patients will continuously take study medications and visit every 3months at the study site. We will measure primary outcome during the follow-up period (minimum 2.8 years to maximum 4 years - maximum time is determined by estimated enrollment time period of 2.8 years).

Sponsor's own description

The purpose of this study is to compare the preventive effect of stroke between triflusal and clopidogrel in ischemic stroke patient based on the cytochrome P450 2C19 (CYP2C19) polymorphism.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Pharmacogenetic testing: Current Evidence of Clinical Utility.
Moaddeb J, Haga SB. · · 2013 · cited 22× · PMID 24020014 · DOI 10.1177/2042098613485595
Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial.
Han SW, Kim YJ, Ahn SH, Seo WK, et al · · 2016 · cited 3× · PMID 26763917 · DOI 10.1177/1747493015620804

Verify or expand the search:

Other trials of Triflusal

Trials testing the same drug.

NCT02904109 — Influence of Triflusal on Cognitive Functions in Subjects Under Chronic Stress · Phase 2 · completed

Other recruiting trials for Cerebral Infarction

Currently open trials in the same condition.

NCT06757764 — The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis · Phase 4 · recruiting
NCT07081568 — Research on Binaural Synchronous Vagus Nerve Regulation of Sensorimotor Disorders After Cerebral Infarction · NA · recruiting
NCT07018167 — Impact of Door-to-Needle Time on Stroke Outcomes at Gonesse Hospital · active not recruiting
NCT04696523 — Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage · Phase 2 · recruiting
NCT06712004 — A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke · Phase 2 · recruiting

Other Gangnam Severance Hospital trials

Trials by the same sponsor.

NCT07505628 — AI-based Rehabilitation for Hip and Knee Surgery Patients · NA · not yet recruiting
NCT07311122 — Endocrine Therapy Base on 21-gene RS · not yet recruiting
NCT07011823 — Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC · Phase 2 · not yet recruiting
NCT07211451 — Axillary Nodal Burden in HER2+ and TNBC · completed
NCT06839716 — Comparison of Ropivacaine-Poloxamer 407 Hydrogel and TAP Block for Postoperative Pain Management in Laparoscopic/Robotic · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01174693 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gangnam Severance Hospital
Last refreshed: 16 March 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01174693.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing